{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007772","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.698912+00:00","generated_at":"2026-06-05T15:09:27.515190+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Matinas reports positive MAT2203 compassionate use data: 12 of 15 patients improved, all completers resolved.","bullets":["19 patients enrolled in compassionate-use program for oral antifungal MAT2203; 15 evaluable.","12 of 15 patients had complete clinical resolution or objective improvement in infection markers.","All 5 patients who completed full treatment (2 weeks to 1 year) had complete resolution with no relapse.","All patients who transitioned from AmBisome due to renal toxicity saw return to baseline renal function.","Patients treated at 9 major institutions including Johns Hopkins, NIH, Memorial Sloan Kettering."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007772","json":"https://secwatch.observer/filing/0001493152-24-007772.json","markdown":"https://secwatch.observer/filing/0001493152-24-007772.md","text":"https://secwatch.observer/filing/0001493152-24-007772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224007772/0001493152-24-007772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224007772/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:09:27.515190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}